GLPwatch
Papers (10401)
Page 31 of 174, ranked by citation count.
- Mildly acidic conditions eliminate deamidation artifact during proteolysis: digestion with endoprotease Glu-C at pH 4.5.
- Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.
- GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice.
- Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice.
- Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
- Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.
- Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus.
- Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials.
- Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.
- A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.
- Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
- The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy.
- Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
- Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway.
- Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
- Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
- Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators.
- Acute Kidney Injury Associated With Semaglutide.
- Spinal microglial β-endorphin signaling mediates IL-10 and exenatide-induced inhibition of synaptic plasticity in neuropathic pain.
- Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
- Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.
- Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling.
- Effects of liraglutide on depressive behavior in a mouse depression model and cognition in the probe trial of Morris water maze test.
- Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial.
- Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.
- Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
- The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception.
- Glucagon-like peptide 1 inhibits the sirtuin deacetylase SirT1 to stimulate pancreatic β-cell mass expansion.
- GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells.
- Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials.
- Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials.
- Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations.
- Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
- Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
- Effects of liraglutide in hypothalamic arcuate nucleus of obese mice.
- Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
- Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways.
- Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
- Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
- Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity.
- An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
- Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
- A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
- Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
- Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis.
- Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.
- Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
- Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.
- Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide.
- Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis.
- Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
- Reversal of Long-Term Weight Regain After Roux-en-Y Gastric Bypass Using Liraglutide or Surgical Revision. A Prospective Study.
- Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
- Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
- Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
- Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
- Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
- PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice.